Literature DB >> 2869722

Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure.

A F Bencini, A H Scaf, Y J Sohn, C Meistelman, A Lienhart, U W Kersten, S Schwarz, S Agoston.   

Abstract

The effect and plasma concentrations of vecuronium bromide were measured in normal patients after an intravenous dose of 50, 100, or 150 micrograms/kg and in patients with renal failure after 50 or 100 micrograms/kg. Urinary excretion of vecuronium was studied in normal patients after the 150 micrograms/kg dose. Pharmacokinetic parameters of patients with or without renal failure were similar. No metabolites of vecuronium were found in the plasma. Twenty percent of vecuronium was excreted unchanged in the urine; 5% as the 3-hydroxy derivative. No other metabolites of vecuronium were found in the urine. Increasing doses of vecuronium shortened the onset, but prolonged the duration of action and the recovery rate, to a similar extent in patients with or without renal failure. It was concluded that the disposition of vecuronium was best described by a three compartment model. Both the disposition and the effect of vecuronium are only marginally disturbed by renal failure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869722

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  21 in total

1.  Do plasma concentrations obtained from early arterial blood sampling improve pharmacokinetic/pharmacodynamic modeling?

Authors:  T M Beaufort; J H Proost; K Kuizenga; M C Houwertjes; U W Kleef; J M Wierda
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

Review 2.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

4.  The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl.

Authors:  J M Wierda; U W Kleef; L M Lambalk; W D Kloppenburg; S Agoston
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

5.  A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs.

Authors:  F Donati; C Meistelman
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

6.  An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs.

Authors:  J H Proost; J M Wierda; D K Meijer
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

Review 7.  Clinical pharmacokinetics of neuromuscular relaxants in pregnancy.

Authors:  J Guay; Y Grenier; F Varin
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

8.  Should vecuronium be used in renal failure?

Authors:  B J Pollard; B R Doran
Journal:  Can J Anaesth       Date:  1989-09       Impact factor: 5.063

9.  Duration of action of supplemental doses of vecuronium is related to the duration after the initial dose.

Authors:  T Otagiri; M Narita; M Nishizawa; C Nishimura
Journal:  J Anesth       Date:  1992-04       Impact factor: 2.078

10.  Pharmacokinetics and pharmacodynamics of vecuronium bromide.

Authors:  T Nomura
Journal:  J Anesth       Date:  1992-01       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.